An observational study in Palonosetron, sponsored by Cttq. Status unknown at 1 site in China. Per ClinicalTrials.gov, last updated 2017-05-11.
Sponsored by Cttq · Observational
Observe palonosetron hydrochloride capsules'(Ruo Shan®) safety and efficacy information in the real world using.
Observe palonosetron hydrochloride capsules'(Ruo Shan®) safety and efficacy information in the real world using.
Observe the adverse effects of palonosetron hydrochloride capsules(Ruo Shan®) that we already known, and whether there is any new adverse effects.Observe the incidence and the situation of adverse effects. Pay attention to the adverse effects in special groups, like pregnant women, children, elderly patients, and patients with liver and kidney dysfunction. Observe other safety issues related to drug using method, drug packaging method and drug quality.
[Time Frame: A period between the first day of using Palonosetron Hydrochloride Capsules (Ruo Shan®) to the fifth day]
Secondary Outcome Measures:
[Time Frame: A period between the first day of using Palonosetron Hydrochloride Capsules (Ruo Shan®) to the fifth day]
Cttq is the lead sponsor of 9 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
A continuous sequence of patients using palonosetron palonosetron hydrochloride capsules(Ruo Shan®)
Exclusion Criteria:
A continuous sequence of patients using palonosetron palonosetron hydrochloride capsules(Ruo Shan®)
Drug: palonosetron hydrochloride capsules
Collect all the patients' safty and efficacy data as long as they use palonosetron hydrochloride capsules(Ruo Shan®) .Specific methods of using the drugs are not limited .
Also known as: Ruo Shan®
Report the palonosetron hydrochloride capsules'(Ruo Shan®) safety information in the real world using.
1. Report the adverse effects of palonosetron hydrochloride capsules(Ruo Shan®) that we already known； 2. Report if there is any new adverse effects； 3. Report the incidence and the situation of the above adverse effects； 4. Report the adverse effects in special groups, like pregnant women, children, elderly patients, and patients with liver and kidney dysfunction； 5. Report other safety issues related to drug using method, drug packaging method and drug quality.
Time frame: A period between the first day of using Palonosetron Hydrochloride Capsules (Ruo Shan®) to the fifth day
Report the efficacy of palonosetron hydrochloride capsules.
Report the control condition of nausea and vomiting.
Time frame: A period between the first day of using Palonosetron Hydrochloride Capsules (Ruo Shan®) to the fifth day
Report the widely used population characteristics.
Report the patients' disease, age, treatment, and chemotherapy drugs.
Time frame: A period between the first day of using Palonosetron Hydrochloride Capsules (Ruo Shan®) to the fifth day
Report the clinical using features of palonosetron hydrochloride capsules.
Report the Using does,time,and frequency of palonosetron hydrochloride capsules,and the concomitant drugs .
Time frame: A period between the first day of using Palonosetron Hydrochloride Capsules (Ruo Shan®) to the fifth day
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cttq